{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T21:08:41Z","timestamp":1779224921415,"version":"3.51.4"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Natalizumab, a therapeutic antibody used to treat multiple sclerosis, undergoes in vivo Fab arm exchange to form a monovalent bispecific antibody. Although highly efficacious, the immunosuppressive activity of natalizumab has been associated with JC polyomavirus-driven progressive multifocal leukoencephalopathy (PML). Development of assays that can distinguish between and quantify bivalent (unexchanged) and monovalent (exchanged) forms of natalizumab in clinical samples may be useful for optimizing extended interval dosing and reducing the risk of PML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In vitro natalizumab arm exchange was conducted, along with peptide mimotope and anti-idiotype surface capture chemistry, to enable the development of enzyme-linked immunosorbent assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      An assay using a unique peptide Veritope\n                      <jats:sup>TM<\/jats:sup>\n                      was developed, which can exclusively bind to bivalent natalizumab. In combination with enzyme-linked immunosorbent assays that quantifies total natalizumab, the assay system allows quantification of both natalizumab forms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this article, a novel assay for the quantification of unexchanged and exchanged natalizumab variants in clinical samples was developed. This assay will enable investigations into the clinical significance of the relationship of PK\/PD with the monovalent-to-bivalent ratio, as it relates to the efficacy of the drug and risk of PML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001038","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T18:00:08Z","timestamp":1665079208000},"page":"55-60","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Peptide Mimotope-Enabled Quantification of Natalizumab Arm Exchange During Multiple Sclerosis Treatment"],"prefix":"10.1097","volume":"45","author":[{"given":"Lesley J.","family":"Page","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Lagunas-Acosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphaela","family":"Heussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward T.","family":"Castellana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley T.","family":"Messmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260519","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/acn3.180","article-title":"Comparative efficacy of switching to natalizumab in active multiple sclerosis","volume":"2","author":"Spelman","year":"2015","journal-title":"Ann Clin Transl Neurol."},{"key":"R2-20260519","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med."},{"key":"R3-20260519","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med."},{"key":"R4-20260519","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin","volume":"356","author":"Yednock","year":"1992","journal-title":"Nature"},{"key":"R5-20260519","doi-asserted-by":"crossref","first-page":"549842","DOI":"10.3389\/fimmu.2020.549842","article-title":"Natalizumab in multiple sclerosis treatment: from biological effects to immune monitoring","volume":"11","author":"Khoy","year":"2020","journal-title":"Front Immunol."},{"key":"R6-20260519","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"Kolfschoten","year":"2007","journal-title":"Science"},{"key":"R7-20260519","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nbt.1553","article-title":"Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo","volume":"27","author":"Labrijn","year":"2009","journal-title":"Nat Biotechnol"},{"key":"R8-20260519","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1007\/s00415-011-6116-8","article-title":"Progressive multifocal leukoencephalopathy and natalizumab","volume":"258","author":"Hellwig","year":"2011","journal-title":"J Neurol."},{"key":"R9-20260519","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","article-title":"Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy","volume":"354","author":"Yousry","year":"2006","journal-title":"N Engl J Med."},{"key":"R11-20260519","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.msard.2019.03.017","article-title":"Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing","volume":"31","author":"Foley","year":"2019","journal-title":"Mult Scler Relat Disord."},{"key":"R12-20260519","doi-asserted-by":"crossref","first-page":"716548","DOI":"10.3389\/fneur.2021.716548","article-title":"Evaluation of natalizumab pharmacokinetics and pharmacodynamics: toward individualized doses","volume":"12","author":"Serra L\u00f3pez-Matencio","year":"2021","journal-title":"Front Neurol."},{"key":"R13-20260519","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","article-title":"Extended interval dosing of natalizumab in multiple sclerosis","volume":"87","author":"Zhovtis Ryerson","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R14-20260519","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/PROM.S41768","article-title":"Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life","volume":"5","author":"Sospedra","year":"2014","journal-title":"Patient Relat Outcome Meas."},{"key":"R15-20260519","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1212\/01.wnl.0000327341.89587.76","article-title":"Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy","volume":"72","author":"St\u00fcve","year":"2009","journal-title":"Neurology."},{"key":"R16-20260519","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1212\/WNL.0b013e3181a8266f","article-title":"Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells","volume":"72","author":"Kivis\u00e4kk","year":"2009","journal-title":"Neurology."},{"key":"R17-20260519","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1001\/archneur.65.12.noc80051","article-title":"Decrease in the numbers of dendritic cells and CD4 + T cells in cerebral perivascular spaces due to natalizumab","volume":"65","author":"Del Pilar Martin","year":"2008","journal-title":"Arch Neurol."},{"key":"R18-20260519","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.80.7_supplement.S30.002","article-title":"Natalizumab related PML: an evolving risk stratification paradigm (S30.002)","volume":"80","author":"Foley","year":"2013","journal-title":"Neurology"},{"key":"R19-20260519","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","article-title":"Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial","volume":"21","author":"Foley","year":"2022","journal-title":"Lancet Neurol."},{"key":"R20-20260519","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1177\/1352458516684023","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations","volume":"23","author":"van Kempen","year":"2017","journal-title":"Mult Scler."},{"key":"R21-20260519","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/bjh.14158","article-title":"VLA-4 blockade by natalizumab inhibits sickle reticulocyte and leucocyte adhesion during simulated blood flow","volume":"174","author":"White","year":"2016","journal-title":"Br J Haematol."},{"key":"R22-20260519","doi-asserted-by":"crossref","first-page":"32314","DOI":"10.1074\/jbc.M113.501668","article-title":"How natalizumab binds and antagonizes \u03b14 integrins","volume":"288","author":"Yu","year":"2013","journal-title":"J Biol Chem."},{"key":"R23-20260519","doi-asserted-by":"crossref","first-page":"14473","DOI":"10.1038\/s41598-018-32832-1","article-title":"Identification of peptide mimotope ligands for natalizumab","volume":"8","author":"Ruff","year":"2018","journal-title":"Sci Rep."},{"key":"R24-20260519","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ab.2011.01.001","article-title":"Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody","volume":"411","author":"Rispens","year":"2011","journal-title":"Anal Biochem."},{"key":"R25-20260519","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/978-1-0716-1186-9_18","article-title":"Recombinant anti-idiotypic antibodies in ligand binding assays for antibody drug development","volume":"2261","author":"Harth","year":"2021","journal-title":"Methods Mol Biol."},{"key":"R27-20260519","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/pro.5560060217","article-title":"Intrachain disulfide bond in the core hinge region of human IgG4","volume":"6","author":"Bloom","year":"1997","journal-title":"Protein Sci."},{"key":"R28-20260519","doi-asserted-by":"crossref","first-page":"5462","DOI":"10.1074\/jbc.M114.600973","article-title":"The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation","volume":"290","author":"Silva","year":"2015","journal-title":"J Biol Chem."},{"key":"R29-20260519","first-page":"20","article-title":"Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab - results of the dose-ranging assessment: international clinical evaluation of rituximab in rheumatoid arthritis (DANCER) trial","volume":"35","author":"Mease","year":"2008","journal-title":"J Rheumatol."},{"key":"R30-20260519","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jpba.2011.01.006","article-title":"Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (Tysabri \u00ae) with endogenous IgG4","volume":"55","author":"Shapiro","year":"2011","journal-title":"J Pharm Biomed Anal."},{"key":"R31-20260519","doi-asserted-by":"crossref","first-page":"e0149330","DOI":"10.1371\/journal.pone.0149330","article-title":"Serum concentrations of IgG4 in the Spanish adult population: relationship with age, gender, and atopy","volume":"11","author":"Carballo","year":"2016","journal-title":"PLoS One"},{"key":"R32-20260519","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1177\/1352458513477229","article-title":"Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients","volume":"19","author":"Selter","year":"2013","journal-title":"Mult Scler J."},{"key":"R33-20260519","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","article-title":"Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function","volume":"72","author":"Khatri","year":"2009","journal-title":"Neurology"},{"key":"R34-20260519","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jns.2011.10.005","article-title":"CD49d expression as a promising biomarker to monitor natalizumab efficacy","volume":"314","author":"Defer","year":"2012","journal-title":"J Neurol Sci."},{"key":"R35-20260519","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/cyto.b.21527","article-title":"Monitoring CD49d receptor occupancy: a method to optimize and personalize natalizumab therapy in multiple sclerosis patients","volume":"94","author":"Pu\u00f1et-Ortiz","year":"2018","journal-title":"Cytometry B Clin Cytom B"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T21:00:10Z","timestamp":1779224410000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001038","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}